Merck Serono and Dr. Reddy's will collaborate on biosimilars
Monoclonal antibodies (MAbs) for oncology will be initial target
The pairing up of innovator pharma companies with generic manufacturers, started with Amgen and Watson Pharma last year, continues with Merck Serono and Dr. Reddy’s. According to a joint company announcement, Merck Serono (Darnstadt, Germany) and Dr. Reddy’s (Hyderabad) will co-develop molecules, with Dr. Reddy’s leading early product development and Phase I trials; then Merck Serono will take over manufacturing and lead Phase III development. Both will share fully in R&D cost-sharing.
Dr. Reddy’s has four biosimilars already launched; the partnership will expand Dr. Reddy’s presence in select emerging markets and to broaden its international reach. Merck Serono will undertake commercialization globally, outside the US and with the exception of select emerging markets which will be co-exclusvie or where Dr. Reddy’s maintains exclusive rights. In the US, the companies will co-commercialize on a profit-sharing basis.
Merck Serono’s existing portfolio includes brands for patients with cancer (Erbitux, cetuximab), multiple sclerosis (Rebif, interferon beta-1a), infertility (Gonal-f, follitropin alfa), endocrine and metabolic disorders (Saizen and Serostim, somatropin), (Kuvan, sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage, metformin), (Concor, bisoprolol), (Euthyrox, levothyroxine). Not all products are available in all markets.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
